The United Kingdom and the United States have concluded a significant commercial pact that will guarantee no levies on UK drug exports being sold in the US market.
Key Provisions of the Deal
In exchange for the tariff guarantee, the UK has agreed to raise spending on drugs through the National Health Service (NHS). This pledge ensures that tariffs on these key exports will be held at zero for a period of the next three years.
This agreement comes after recent warnings to significantly raise import taxes on branded pharmaceutical imports, with increases mentioned as high as double the cost.
"This arrangement between the UK bolsters the international landscape for new treatments and introduces much-needed equity to American-British pharmaceutical trade," a statement said.
Trade Importance
Drugs constitute one of the the United Kingdom's biggest exports to the United States, which is clearly the primary buyer for large companies like GSK and AstraZeneca.
Trade data reveal that in the one-year period prior to the third quarter, the UK shipped pharmaceutical products valued at £11.1bn to the US. This value accounted for nearly one-fifth of all goods exports in that timeframe.
"This agreement protects jobs, stimulates investment and sets the stage for the UK to become a worldwide center for biotech and pharma," a minister stated.
Key NHS Changes
The agreement involves several specific changes from the British government:
- Revised Affordability Limit: The UK will raise the affordability limit at which it judges new medicines to be too expensive by a quarter.
- Boosted Medicine Funding: There is a aim to increase overall NHS spending on medicines from 0.3% of Gross Domestic Product to 0.6 percent over the coming ten years.
- Payback Limit: The sum drug companies must refund to the NHS to control costs will be restricted at 15%. Previously, repayments were more than twenty percent.
Recent Tensions
The deal follows a ongoing row between the pharmaceutical industry and the ministers over medicine costs and approval rates.
The disagreement were exacerbated by claims that US consumers were charged several times more for the same drugs than consumers in the other developed nations.
In recent months, several major pharmaceutical investments in the UK have been halted or cancelled, while multi-billion-dollar investments have been directed toward American operations.
A senior figure stated that the NHS had to invest a greater share on medicines, noting that its expenditure on drugs had decreased as a share of its total funding over the previous ten-year period.
